Spyre Therapeutics to Participate in Upcoming November Investor Conferences

GlobeNewswire

昨天

WALTHAM, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (「IBD」) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:

Event: Guggenheim 2^nd Annual Healthcare Innovation Conference - Boston
Date: Monday, November 10, 2025
Fireside Time: 10:00 am ET

Event: Stifel 2025 Healthcare Conference – New York
Date: Tuesday, November 11, 2025
Fireside Time: 8:40 am ET

Event: Jefferies Global Healthcare Conference - London
Date: Wednesday, November 19, 2025
Fireside Time: 8:00 am GMT

Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (「IBD」) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, visit Spyre's website at www.spyre.com.

For Investors:
Eric McIntyre, Spyre Therapeutics
VP of Finance and Investor Relations
Eric.mcintyre@spyre.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2579513488"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579513488\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579513488?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579513488","market":"us","top_or_hot":-1,"title":"Spyre Therapeutics to Participate in Upcoming November Investor Conferences","media":"GlobeNewswire","content":"<html><body><p>WALTHAM, Mass., Oct.  29, 2025  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/SYRE\">Spyre Therapeutics</a>, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (「IBD」) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:</p> <p><strong>Event: Guggenheim 2</strong><sup><strong>nd</strong></sup><strong> Annual Healthcare Innovation Conference - Boston</strong><br/><strong>Date: </strong>Monday, November 10, 2025<br/><strong>Fireside Time: </strong>10:00 am ET</p> <p><strong>Event: <a href=\"https://laohu8.com/S/SFB\">Stifel</a> 2025 Healthcare Conference – New York</strong><br/><strong>Date: </strong>Tuesday, November 11, 2025<br/><strong>Fireside Time: </strong>8:40 am ET</p> <p><strong>Event: Jefferies Global Healthcare Conference - London</strong><br/><strong>Date: </strong>Wednesday, November 19, 2025<br/><strong>Fireside Time: </strong>8:00 am GMT</p> <p>Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.</p> <p><strong>About Spyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></strong></p> <p>Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (「IBD」) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.</p> <p>For more information, visit Spyre's website at www.spyre.com.</p> <p><strong>For Investors:</strong>      <br/>Eric McIntyre, Spyre Therapeutics<br/>VP of Finance and Investor Relations<br/>Eric.mcintyre@spyre.com </p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/YWJhNDQxYzctZDVjMi00YTBlLTkyZjktMjVlOWNhMzg4MjE3LTEzMDYzNjMtMjAyNS0xMC0yOS1lbg==/tiny/Spyre-Therapeutics-Inc-.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spyre Therapeutics to Participate in Upcoming November Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpyre Therapeutics to Participate in Upcoming November Investor Conferences\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time smaller\">2025-10-30 04:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>WALTHAM, Mass., Oct.  29, 2025  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/SYRE\">Spyre Therapeutics</a>, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (「IBD」) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:</p> <p><strong>Event: Guggenheim 2</strong><sup><strong>nd</strong></sup><strong> Annual Healthcare Innovation Conference - Boston</strong><br/><strong>Date: </strong>Monday, November 10, 2025<br/><strong>Fireside Time: </strong>10:00 am ET</p> <p><strong>Event: <a href=\"https://laohu8.com/S/SFB\">Stifel</a> 2025 Healthcare Conference – New York</strong><br/><strong>Date: </strong>Tuesday, November 11, 2025<br/><strong>Fireside Time: </strong>8:40 am ET</p> <p><strong>Event: Jefferies Global Healthcare Conference - London</strong><br/><strong>Date: </strong>Wednesday, November 19, 2025<br/><strong>Fireside Time: </strong>8:00 am GMT</p> <p>Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.</p> <p><strong>About Spyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></strong></p> <p>Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (「IBD」) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.</p> <p>For more information, visit Spyre's website at www.spyre.com.</p> <p><strong>For Investors:</strong>      <br/>Eric McIntyre, Spyre Therapeutics<br/>VP of Finance and Investor Relations<br/>Eric.mcintyre@spyre.com </p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/YWJhNDQxYzctZDVjMi00YTBlLTkyZjktMjVlOWNhMzg4MjE3LTEzMDYzNjMtMjAyNS0xMC0yOS1lbg==/tiny/Spyre-Therapeutics-Inc-.png\"/></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SYRE","symbol_name":"SPYRE THERAPEUTICS INC","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176866/0/en/Spyre-Therapeutics-to-Participate-in-Upcoming-November-Investor-Conferences.html","article_id":"2579513488","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579513488","pubTimestamp":1761768300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"WALTHAM, Mass., Oct.  29, 2025  (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redef","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SYRE":"SPYRE THERAPEUTICS INC","XBI":"SPDR S&P Biotech ETF","BK4581":"高盛持仓","XLV":"健康照护类股ETF-SPDR","BK4007":"制药","LENZ":"Therapeutics","BK4539":"次新股","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LABU":"三倍做多标普生物-Direxion"},"translate_title":"Spyre Therapeutics将参加即将举行的11月投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":0.6,"LENZ":1.5,"SYRE":1,"XBI":0.6,"XLV":0.9},"content_text":"WALTHAM, Mass., Oct.  29, 2025  (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (「IBD」) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences: Event: Guggenheim 2nd Annual Healthcare Innovation Conference - BostonDate: Monday, November 10, 2025Fireside Time: 10:00 am ET Event: Stifel 2025 Healthcare Conference – New YorkDate: Tuesday, November 11, 2025Fireside Time: 8:40 am ET Event: Jefferies Global Healthcare Conference - LondonDate: Wednesday, November 19, 2025Fireside Time: 8:00 am GMT Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations. About Spyre Therapeutics Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (「IBD」) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com. For Investors:      Eric McIntyre, Spyre TherapeuticsVP of Finance and Investor RelationsEric.mcintyre@spyre.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}